Pacific Edge Appoints Anna Stove as Independent Director

Pacific Edge is pleased to welcome Anna Stove as an independent Director, effective from 15 March 2021.

Anna has global executive experience and a successful 25+ year track record in leading and driving transformational change within the healthcare sector. She has held a number of governance roles with private and listed organisations and is currently Chair of Global Women New Zealand and a director of Rua Bioscience and TAB NZ. Anna was the General Manager of GlaxoSmithKline New Zealand for seven years and prior to that, held a number of senior roles with multinational science-led healthcare companies across Europe and Asia.

Anna said: “I am excited to be joining the Pacific Edge Board. I’ve been impressed with Pacifc Edge’s patient centric approach for their Cxbladder tests, which is positively disrupting the urology landscape globally. I’m looking forward to working with Chris and the team to accelerate the company’s global growth.”

Chair of Pacific Edge, Chris Gallaher, commented: “We are delighted to welcome Anna to the Board. Her extensive international experience in the science and healthcare sectors will be of value to Pacific Edge as we continue with our growth strategy. We are at an exciting time in Pacific Edge’s commercial journey as we build on the major commercial milestones achieved in 2020 in our primary market, the USA, including coverage from the Centres for Medicare and Medicaid and commercial agreement with Kaiser Permanente, the largest integrated healthcare provider in the US.”

Anna Stove has been appointed by the current Pacific Edge Directors, as permitted under Pacific Edge’s constitution. She will hold office until Pacific Edge’s 2021 Annual Meeting at which time she will offer herself for election by shareholders. The Board has determined that Anna will be an independent Director.